Revive Therapeutics : RVV Investor Fact Sheet Q4 2023a

	Corporate Fact Sheet Q4-2023
OVERVIEW
∙ Developing novel therapeutics and diagnostics for	∙ Robust patent portfolio (16 patents and patent applications)
infectious diseases, mental health and rare disorders	∙ Prioritize development efforts targeting FDA regulatory
∙ Advancing novel use of Bucillamine for COVID-19 and	incentives designations (i.e. Orphan Drug, Fast Track,
companion long COVID diagnostic	Breakthrough Therapy and Rare Pediatric Disease)
∙ Novel uses and patch delivery of Psilocybin

PRODUCT PIPELINE

EXPECTED MILESTONES Q1-2024

Complete reformulation of Bucillamine IV for future studies in infectious diseases and ischemia-reperfusion

FDA meeting for Long COVID Lab and Rapid Test development

FDA meeting for Bucillamine to treat Long COVID

Results of Bucillamine for nerve agent exposure at DRDC

Interim results for Phase 1/2 study - Psilocybin in Methamphetamine Disorder at University of Wisconsin

FDA pre-IND meeting for Psilocybin patch

Initiate IND-enabling studies for MDMA patch

CONTACT INFOMATION

Revive Therapeutics Ltd.

82 Richmond Street East

Toronto, ON M5C 1P1

Tel: [phone]

E-mail:[e-mail]

Website:revivethera.com

STRATEGIC PARTNERS

TEAM

Management

Michael Frank, Chairman & CEO

Carmelo Marrelli, CFO

Derrick Welch, COO, Psilocin Pharma

Scientific and Clinical

Dr. Kelly McKee, CSO Dr. Arshi Kizilbash, M.D.

Dr. Osnesmo Mpanju, Regulatory Affairs

Dr. John Fahy, MD, Clinical and Scientific Advisor Dr. Douglas Fraser, Scientist, Critical Care Physician

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

STOCK INFORMATION

Ticker:	CSE: RVV, OTCQB: RVVTF,
FRANKFURT: 31R
Share Price:	$0.03 (Nov 3, 2023)
52-week High / Low:	CAD $0.275 / $0.02
Shares Outstanding:	357,646,841
Market Cap:	CAD ~ 10,500,000